Accueil / Communiqués / OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter

OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter

Monday, February 11th 2019 at 8:00am UTC

— Addition of 2nd independent board member positions OMEICOS well
for future value creation —

BERLIN & BOSTON–(BUSINESS WIRE)– OMEICOS Therapeutics, a biopharmaceutical company developing
first-in-class small molecule therapeutics for the prevention and
treatment of cardiovascular and ophthalmic diseases, today announced the
appointment of Christian Schetter, Ph.D., as an independent Board
Member. Christian has over 20 years’ industry experience across the life
sciences sector, and most recently joined venture capital firm Arix
Bioscience plc as an Entrepreneur in Residence. Before that he was
instrumental in building German immuno-oncology company Rigontec GmbH as
their CEO and managed the integration process after Rigontec was
acquired by MSD in 2017. His appointment adds a second independent board
member to the OMEICOS board complementing the position of Dr. Bernd
Kirschbaum as Chairman of the Supervisory Board.

Dr. Bernd Kirschbaum, Chairman of the Supervisory Board commented:
“Bringing Christian on board, an experience leader who has gone through
the process of building up biopharmaceutical start-ups, delivering on
the important value inflection points in R&D and taking the next steps
in corporate development, adds valuable expertise to the OMEICOS board.
With two independent board members, in addition to the experienced board
representation from our investors already in place, OMEICOS is well
equipped for the next corporate development steps.”

“We welcome Christian to our Supervisory Board and are looking forward
to working with him as OMEICOS enters a very exciting stage in its
development. Christian’s appointment adds a second independent board
member to our team, following Bernd Kirschbaum’s addition to the board
in 2015 whose years of R&D leadership at pharmaceutical companies have
been and will continue to be essential as we advance our lead compound
in Atrial Fibrillation towards proof-of-concept in patients and continue
expanding our development pipeline with our subsidiary OMEICOS
Ophthalmics in Boston. Taken together, Bernd and Christian bring two
unique sets of experience and expertise to OMEICOS,” added Robert
Fischer, MD, CEO/CSO of OMEICOS Therapeutics.

Prior to his role at Rigontec GmbH, Christian was President and CEO of
Neovii Biotech (previously Fresenius Biotech). During his tenure, one
antibody product was brought to market and the indication for another
product expanded. Christian was also instrumental in selling Fresenius
Biotech to the Neopharm Group, Israel, to form Neovii Biotech and
positioning it as a successful standalone business. He was SVP of
European Operations at Coley Pharmaceutical Group and Managing Director
of Coley GmbH. Christian was part of the leadership team which built
Coley Pharmaceuticals from inception through multiple financing rounds,
a NASDAQ IPO and, following several significant pharma deals, to a trade
sale to Pfizer in 2007. Before entering the life science industry,
Christian was successfully performing academic research at the Max
Planck Institute in Martinsried, Germany. He received his undergraduate
degree and PhD from the University of Cologne and did postdoctoral
research in oncology and virology at the Scripps Research Institute in
La Jolla, California.

About OMEICOS

OMEICOS Therapeutics is a spin-off company from the Max Delbrueck Center
for Molecular Medicine (MDC) in Berlin. The company has discovered a
series of metabolically robust synthetic analogues of omega-3 fatty
acid-derived epoxyeicosanoids that have the potential to treat
inflammatory, cardiovascular and other diseases. Epoxyeicosanoids, as a
newly described class of bioactive lipid mediators, activate cell
type-specific endogenous pathways that promote organ and tissue
protection. OMEICOS’ small molecules are orally available and show
improved biological activity and pharmacokinetic properties compared to
their natural counterparts. OMEICOS’ technology is based on
ground-breaking scientific results in the field of omega-3 fatty acid
metabolism and physiology obtained by the companies’ founders, Dr.
Wolf-Hagen Schunck, Prof. John. R. Falck, Prof. Dominik Mueller and Dr.
Robert Fischer. The companies’ research activities are supported by a
grant from the German Ministry of Education and Research (BMBF). www.omeicos.com

Contacts

OMEICOS Therapeutics GmbH
Dr. Robert Fischer, CEO, CSO
Phone:
+49 (0) 30 9489 4810
E-Mail:
r.fischer@omeicos.com
www.omeicos.com

Media requests:
MacDougall Biomedical Communications
Mario
Brkulj or Amanda Whelan
Main: +49 89 2424 3494 or +1 781-235-3060
E-Mail:
omeicos@macbiocom.com

Source: OMEICOS Therapeutics


Voir aussi

Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital

Friday, February 22nd 2019 at 10:20pm UTC IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)– Urovant Sciences …